The Death of Clomid
In 2018 The American College of Obstetricians and Gynecologists (ACOG) released their endorsement of Letrozole (femara) as first-line treatment for women with PCOS and infertility. Both the American Society for Reproductive Medicine (ASRM) and ACOG agree that letrozole is the best agent for ovulation induction for PCOS and infertility.
Additional benefits include:
1. Less psychological consequences
2. Increased pregnancy rates
3. Easier lining on the uterus
A recent study and clinical trial presented at the 2012 ASRM conference showed 25% percent of women treated with letrozole had a live birth compared to the 16.8% of women who took Clomid. Researchers found that women treated with letrozole not only were more likely to ovulate than were women treated with the standard drug, clomid, but were also more likely to have a live birth.
Kaplan-Meier Curve for Live Birth Chart*
According to Dr. Samuel E. Brown, “The famous pill has died. We as Reproductive Endocrinologists and Infertility Specialists have abandoned clomid over 10 years ago and no longer teach OBGYN residents to use it for infertility patients. Using letrozole has proven great success rates without the side effects of clomid, all the while being just as affordable. We at Brown Fertility fully endorse it.”
Traditionally, clomid has been a more cost-effective treatment option for patients versus letrozole. However, today letrozole is just as affordable. Prescription drug prices are not regulated and the cost of a prescription may differ between pharmacies.
With over 30 years’ experience, and the management of more than 5,000 IVF cycles, the providers at Brown Fertility consistently achieve success rates above the national average. From basic evaluation and testing to the most advanced procedures and treatments available, Brown Fertility is dedicated to Conceiving Miracles™.
*Source:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175743/